Stem Cell Therapy for Diabetes
THE ONLY NATURAL TREATMENT FOR DIABETES THAT REALLY CURES DIABETES AND REALLY WORKS!!! Stem Cell Therapy for Diabetes Diabetes has been one of those diseases which cause ...

By: Robert Esser

Read this article:
Stem Cell Therapy for Diabetes - Video

Recommendation and review posted by simmons

Stem cell technology representsone of the most fascinating and controversial medical advances of the past several decades. By now the enormous controversy which surrounded the use of federal funds to conduct scientific research on human stem cells during the George W. Bush administration has largely blown over. Five years have passed since President Obama lifted federal funding restrictions, and amazing progress has already been made in the field.

One can make a good case for stem cells being the most fascinating and versatile cells in the human body. This is precisely due to their stem role. In their most basic form, theyre capable of both replicating themselves an unlimited number of times and differentiating themselvesinto a huge number of other cell types. Muscle cells, brain cells, organ cells, and many others can all be created from stem cells. If youre interested, the NIH has an awesome introductionon stem cells on their website.

The question which has arisen since the discovery of thisamazing cell type has been how to harness their power and versatility. This is the primary focus of research today: how can we precisely control stem cells to perform whatever tasks we need them to do? Of course, other important issues, such as figuring out thebest places from which to harvest stem cells,exist.

Because of their role in the body, the number of potential applications for stem cells are truly stunning. From building custom cell clusters with 3D printers to curing a variety of diseases through bone marrow transplants, growingorgans for transplants, andeven growing edible meat, research is progressing at a frantic pace.

There are two particular areas of research which seem to hold the greatest promise at this point. The first is organs. Anyone who has ever been involved in an organ transplant knows how incredibly complex and difficult the process is. But difficulties like finding the right donor, preserving the organ, and finding enough supply to meet the incredible demand could all be overcome if we could simply use stem cells to grow a custom organ for each transplant from scratch.

Besides this perhaps science-fiction-sounding process of growing organs, theres also incredible excitement surrounding the potential of bone marrow transplants to cure diseases like HIVand Leukemia. This is done by implanting stem cells containing genetic mutations which confer immunity to a variety of diseases into a patients bone marrow, where they can begin naturally replicating and affecting the immune system.

Thisprocedurealso covers transplants designed simply to reintroduce healthy stem cells to help tackle a wider variety of ailments. Often, referred to as regenerative medicine as itinvolves stimulating the bodys preexisting repair mechanisms to help the healing process,thisprocedurealso offer great promise.

Naturally, the speed at which advances are being made in the field has led to problems as well. One recent well-publicized study which seemed to point to the possibility of achieving stimulus-triggered acquisition of pluripotency (essentially demonstrating a new type of stem cells) is now believedto have beenfraudulent.

Continued here:
The Future of Stem Cells: Opportunities at the Cutting Edge of Science

Recommendation and review posted by Bethany Smith

Proud new dad Jason Manford has shared his baby joy over the weekend after welcoming his fifth child into the world.

But the birth has also given the comic and his girlfriend Lucy the opportunity to save a life.

The couple decided to take the unusual step of donating the umbilical cord and placenta to the Anthony Nolan Trust after meeting its team at St Marys Hospital.

The charity helps people with blood cancers matching them with donors if they need a stem cell, bone marrow or cord blood transplant.

It runs an umbilical cord and placenta collection programme in eight hospitals across the country, including St Marys.

Specialists collect the umbilical cord and placenta from donors after the birth and, instead of throwing them away, extract blood from them.

Stem cells in cord blood are adaptable which makes finding matches for donors easier and, as they are stored in a bank, they are available straight away.

Its a fantastic scheme and Jason has done a great service by raising awareness of it. Wed encourage any expecting parents to follow in his footsteps and find out more.

To find out more, go to their website.

VIEW GALLERY

More here:
MEN Comment: Join Jason Manford in donating to Anthony Nolan donor scheme

Recommendation and review posted by Bethany Smith

The Specimen-Teaser
Official Teaser trailer for The Specimen. Current planned platforms: Wii U eShop PC (steam) -Hyper Galaxy Studios Abducted from your home planet by a highly intelligent race obsessed with...

By: Hyper Galaxy Studios

Here is the original post:
The Specimen-Teaser - Video

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass. (TheStreet) -- Foundation Medicine (FMI) will become majority-owned by Roche (RHHBY) as part of a $1 billion-plus strategic partnership to expand the use of genetic testing in cancer drug research and treatment, the companies announced today.

Roche's acquired stake in Foundation Medicineis priced at $50 per share, more than double the company's Friday closing price of $23.93. Foundation Medicine will continue to operate independently.

Must Read: Jim Cramer's Five Best Stock Picks for the Biotech Sector

The investment and strategic collaboration between Roche and Foundation Medicine was announced on the eve of the closely followed J.P. Morgan Healthcare Conferencein San Francisco.

Foundation Medicine analyzes the genetic signature of tumors to help doctors match patients with the optimal cancer treatment -- both approved drugs or clinical trials of experimental therapies. The company's two commercially available tests analyze solid tumors and blood-based cancers to find specific genetic mutations.

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more:
Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

Recommendation and review posted by Bethany Smith

Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments.

Dr. Michael J. Pellini, chief executive of Foundation, told CNBC on Monday the deal can accelerate a move into precision medicine for oncology.

"It's an important day for patients battling cancer," he said in a "Squawk Box" interview, noting that Foundation helps doctors understand cancer at its blueprint and then deploy targeted therapeutics.

Roche will pay $50 a share, or about $780 million, a premium of 109 percent to Foundation's closing price Friday. Roche will also invest $250 million in Foundation by acquiring newly issued shares.

As a result, Roche will own 52.4 percent to 56.3 percent of Foundation. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.

Reuters contributed to this report.

More here:
$1.8B drug deal to target cancer at genetic level

Recommendation and review posted by Bethany Smith

Roche Holding AG agreed to pay $1.03 billion for up to a 56.3% stake in Foundation Medicine Inc. FMI, +109.03% in a collaboration that underscores the growing importance of genetic diagnostics in the treatment and development of drugs for cancer.

Under the agreement, Roche ROG, +2.23% RHHBY, +0.50% will launch a tender offer for about 15.6 million shares of the Cambridge, Mass., maker of molecular diagnostic tests for about $780 million, or $50 a share, and it will also acquire five million new shares of the company, also for $50 each. The amount is a 109% premium over Foundations closing price of $23.93 on Friday.

Foundation has developed and markets two testsone for solid tumors such as lung cancer and melanoma and one for blood cancers such as leukemiathat use next-generation genetic sequencing to identify mutations that are the drivers of a patients disease. Doctors can use the results to try to match patients with available drugs that target the identified mutations or with clinical trials testing such drugs.

This personalized medicine approach is helping to transform cancer treatment and prompting an intense search among drug and biotechnology companies for new driver mutations and drugs that take aim at them.

Under the agreement, in addition to the equity, Roche may invest at least an additional $150 million for research and development collaboration between the two companies. The R&D will include using the tests in the development of drugs in Roches pipeline, said Michael Pellini, Foundations president and chief executive officer.

As part of the agreement, Roche will market the tests outside the U.S. and support Foundations commercial efforts in the U.S., Dr. Pellini said.

A full version of this article can be found at WSJ.com

View post:
The Wall Street Journal: Roche Holding to pay $1.03 billion for stake in Foundation Medicine

Recommendation and review posted by Bethany Smith

New research provides insights into the ties between certain genetic variants and kidney disease in African Americans. The genetic association is one of the strongest ever reported for a common disease, and these latest findings may help improve diagnosis and treatment. The study appears in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

African Americans have a 4-fold increased risk for chronic kidney disease compared with European Americans. Recent work from several research groups has shown that much of this risk is due to genetic variations in a gene called apolipoprotein L1 (APOL1), which creates a protein that is a component of HDL, or good cholesterol. These variants arose tens of thousands of years ago in sub-Saharan Africa, and so are present in individuals who have recent sub-Saharan African ancestry. Approximately 5 million African Americans carry APOL1 risk variants, placing them at increased risk for kidney disease.

Jeffrey Kopp, MD (National Institutes of Health) and his colleagues investigated the role of APOL1 variants in a particular form of kidney disease called focal segmental glomerulosclerosis (FSGS). The team studied information on 94 patients with FSGS and found that patients who had APOL1 variants tended to have more advanced disease when they were diagnosed, which fits with prior observations that this genetic form of FSGS progresses rapidly. Previous research has shown that patients with two APOL1 variants respond to glucocorticoids with reductions in urinary protein excretion, but they nonetheless may experience progressive loss of kidney function. The present study showed a similar pattern with cyclosporine and mycophenolate mofetil. "New therapies targeting APOL1 injury pathways are needed, as standard therapies do not work for many people with this gene variant," said Dr. Kopp.

The investigators also found that 72% of self-identified African Americans in the study had APOL1 risk variants, similar to earlier findings. "We also found the APOL1 risk genotype in 2 individuals of Hispanic descent, which is well known, and in 2 individuals who self-identified as White, or European American, which has not been reported before. This last finding suggests that APOL1 risk variants can be present in individuals who self-identify in various ways," said Dr. Kopp.

In an accompanying editorial, Christopher Larsen, MD (Nephropath) and Barry Freedman, MD, PhD (Wake Forest School of Medicine) write that "the report by Kopp et al. enhances our understanding of a common etiology of the FSGS lesion seen on kidney biopsy in African Americans." They note, however, that the findings from the trial, although informative, are not encouraging due to the poor outcomes that patients with APOL1 variants often ultimately experience.

Story Source:

The above story is based on materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.

The rest is here:
Insights into role of genetic variants in kidney disease

Recommendation and review posted by Bethany Smith

Update: french touch genetics
Douce nuit. Aka Hindu kush x northern lights. Just hit flowering lets see what she does.

By: (RMC)rockymountaincultivators

Follow this link:
Update: french touch genetics - Video

Recommendation and review posted by Bethany Smith

By RTT News, January 12, 2015, 08:18:00 AM EDT

(RTTNews.com) - Seattle Genetics, Inc. ( SGEN ) and Bristol-Myers Squibb Co. ( BMY ) Monday said they have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics' antibody-drug conjugate, or ADC, Adcetris (brentuximab vedotin) and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.

The first trial will evaluate the combination of Adcetris and Opdivo as a potential treatment option for patients with relapsed or refractory Hodgkin lymphoma or HL, and the second trial will focus on patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma.

Adcetris is an ADC directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with the potency of a cell-killing agent. Opdivo is a human programmed death receptor-1 blocking antibody that binds to the PD-1 receptor expressed on activated T-cells.

The studies are expected to begin in 2015, with Seattle Genetics conducting the HL trial and Bristol-Myers Squibb conducting the NHL trial.

Adcetris is approved in relapsed HL and systemic anaplastic large cell lymphoma, but is not currently approved for the treatment of relapsed, transplant eligible HL or for the treatment of other types of NHL. Opdivo is currently not approved for the treatment of lymphoma.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

See more here:
Seattle Genetics, Bristol-Myers Report Clinical Trial Collaboration

Recommendation and review posted by Bethany Smith

Gene therapy for cancer and other diseases
The recent two decades have seen dramatic progress in gene therapy, both scientifically and socially. We are now able to treat several single gene disorders, decreasing disease and saving lives,...

By: Oxford University Department for Continuing Education

Continue reading here:
Gene therapy for cancer and other diseases - Video

Recommendation and review posted by Bethany Smith

4 Gene Therapy

By: guj studyboard

See the rest here:
4 Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Gene Therapy To Restore Hearing Loss - Nov 2014
KANSAS CITY, Kan. Restoring hearing with a drug is the goal of a metro researcher. Now he #39;s begun the first study in humans of a gene therapy that could help people hear again. Rob Gerk...

By: sixesfullofnines

Continue reading here:
Gene Therapy To Restore Hearing Loss - Nov 2014 - Video

Recommendation and review posted by Bethany Smith

Bionic Legs Help Spinal Cord Patient Walk | Video
A powered exoskeleton from Ekso allows stroke victims and partial spinal cord injury patients, like Shane Mosko, to walk farther, aiding rehabilitation.

By: LiveScienceVideos

Original post:
Bionic Legs Help Spinal Cord Patient Walk | Video - Video

Recommendation and review posted by sam

Potential breakthrough in regenerative medicine
Scientists in Los Angeles found a way to engineer organs that can help babies with intestinal failure. Also, new warnings about HPV infections. Eboni William...

By: CBSNews.com Web Extras

See more here:
Potential breakthrough in regenerative medicine - Video

Recommendation and review posted by sam

Spinal Cord Injury standing Independently at NeuroFit360
"Goals on the road to achievement can not be achieve without discipline and consistency." Relearning how to stand after 5 years post injury at NeuroFit360. F...

By: Guy Romain

See the rest here:
Spinal Cord Injury standing Independently at NeuroFit360 - Video

Recommendation and review posted by sam

If youre between 17 and 35 years old, you may be able to save Chris LeBruns life.

LeBrun, 48, was diagnosed with leukemia last May. The accountant and father of two learned last fall that he needs a stem cell donation to beat the disease.

But the donor cant be just anyone. It has to be someone who is a match for the genetic markers in the proteins of LeBruns white blood cells.

That sounds complicated, but the test to find a genetic match is quite simple. Just by swiping the inside of the mouth with a cotton swab, enough cells are collected to determine whether a match has been found.

Donors between 17 and 35 are accepted, and males are preferred, as transplants from men tend to be more successful.

On Saturday in Bedford, 36 people joined the stem cell registry through Canadian Blood Services to try to help LeBrun and others with certain forms of cancer, bone marrow deficiency diseases, anemia and other immune system and metabolic disorders.

LeBrun lives in Cambridge, Ont., but has deep ties to Nova Scotia, says his longtime friend, Barb Leighton.

Leighton describes her friend as a community leader who volunteers tirelessly for causes that are important to him.

Hes very quiet, very humble, very modest, not at all for attention. Complete, pure altruism, she says.

It seems that LeBruns community spirit runs in the family. His great-uncle, Gerald LeBrun, was a well-regarded Bedford doctor who regularly made house calls long after that practice fell out of fashion. Saturdays stem cell clinic was held at the LeBrun Recreation Centre, which was named after the doctor.

Read this article:
Bedford clinic seeks stem cell match for man with leukemia

Recommendation and review posted by Bethany Smith

We also showed that adding an active human BCL11A gene to human or mouse breast cells in the lab drove them to behave as cancer cells.

As important, when we reduced the activity of BCL11A in three samples of human triple-negative breast cancer cells, they lost some characteristics of cancer cells and became less tumorigenic when tested in mice.

So by increasing BCL11A activity we increase cancer-like behaviour; by reducing it, we reduce cancer-like behaviour.

Around 10,000 people a year are diagnosed with triple-negative breast cancer. The disease does not respond to traditional breast cancer drugs like Herceptin and is one of the most aggressive types.

Just 77 per cent of people with triple-negative breast cancer will survive for five years, compared with 93 per cent for other types of the disease.

For the new study, researchers looked that the genetic profile of tumours from 3,000 patients, specifically searching for genes which affect how stem cells and tissues develop.

Higher activity of the BCL11A gene was found in approximately eight out of ten patients and was associated with a more advanced grade of tumour.

To test the theory that the gene was promoting tumour growth, scientists genetically engineered mice to have inactive copies. None of the animals went on to develop tumours in the mammary gland, whereas all untreated animals developed tumours.

This exciting result identifies a novel breast cancer gene in some of the more difficult-to-treat cases, said Professor Carlos Caldas, Director of the Cambridge Breast Cancer Research Unit at the University of Cambridge.

It builds on our work to develop a comprehensive molecular understanding of breast cancer that will inform clinical decisions and treatment choices.

More:
Breast cancer breakthrough as Cambridge University finds gene behind killer disease

Recommendation and review posted by Bethany Smith

Bioethics Project - Should we perform prenatal genetic engineering in humans?
By Samantha, Eliesse and Nicole.

By: Samantha Hill

More:
Bioethics Project - Should we perform prenatal genetic engineering in humans? - Video

Recommendation and review posted by Bethany Smith

I would like to start this Topic with a discussion on the contents of the ancient Sumerian Tablets where genetic engineering experiments were done:

1. to create humans or human-like species (Neanderthals) through mixing human gene with the apeman's gene, and

2. to alter the features of humans.

Through this discussion, we can evaluate the possibilities of whether ancient genetic engineering experiments may have been responsible for some of the weird looking bones, which had been found and which are being considered as evidences of evolution.

But before I start a discussion on the contents of the Sumerian Tablets, I am going to explain a little about the contents of the ancient Sumerian Tablets here, so that the reader will understand why I am using the Sumerian Tablets in my discussion here. Then, I will connect the genetic engineering experiments, and other contents in the Sumerian Tablets, to the Neanderthals and Cro Magnons. Then, I will be discussing the following:

1. the possibilities of evolution of the apeman to the present day man

2. how the Replitians had paved the way for ET and evolution believers (just as they had paved the way for Buddha, Abraham, Christ, and Mohammad).

3. the possibilities of ancient genetic engineering experiments that may have created and / or aggravated the Rh negative blood situation (I will be connecting the Cro Magnons to this discussion relating to the Rh negative blood; and I will also be discussing the elongated skulls, giants etc).

I will be discussing the Sumerian Tablets later, in another Topic, so as to give explanations on the story in the Sumerian Tablet. So I am not going to explain, the contents of the Sumerian Tablets, to a great extent here.

You will be able to read the translations of the contents of the Sumerian Tablets (in videos), through the link:

Read the original:
Evolution, the Creation Theory or Genetic Engineering ...

Recommendation and review posted by Bethany Smith

The Sims 3 - Perfect Genetics Challenge Ep.64 Candy #39;s Surprise
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

Read more here:
The Sims 3 - Perfect Genetics Challenge Ep.64 Candy's Surprise - Video

Recommendation and review posted by Bethany Smith

How Nutrition and Genetics Affect Dental Health with Dr. Jack Gruber DDS
Dr. Jack Gruber DDS discusses how nutrition and genetics affect dental health. Visit http://www.periclean.com for more information.

By: PeriClean Toothbrush

Read more:
How Nutrition and Genetics Affect Dental Health with Dr. Jack Gruber DDS - Video

Recommendation and review posted by Bethany Smith

Sharing cannabis genetics?

By: carpo719

Read the rest here:
Sharing cannabis genetics? - Video

Recommendation and review posted by Bethany Smith

HOPE, HYPE REALITY: SCIENTIFIC RATIONALE FOR GENOME EDITING
Why we consider gene therapy to be a viable means to control or cure HIV.

By: defeatHIV

Original post:
HOPE, HYPE & REALITY: SCIENTIFIC RATIONALE FOR GENOME EDITING - Video

Recommendation and review posted by Bethany Smith

A brother and sister who launched a campaign to encourage people to join the bone marrow register after their mother was diagnosed with leukemia say it has helped save five peoples lives.

Jonni and Caroline Bergerorganised the #Spit4Mum campaign after Sharon Berger, who lives in Kenton and was then 61, was diagnosed with leukemia on Boxing Day 2012.

Doctors said a transplant was her only chance of survival but that finding a donor could be difficult, as Jewish people were underrepresented on the Anthony Nolan bone marrow register.

Since the #Spit4Mum campaign, five people who joined theregister have already gone on to donate their stem cells to people in need of a transplant.

Jonni Berger, 35, said: Our family are thrilled that #Spit4Mum has been so successful and that in such a short space of time, five families, devastated by life-threatening illnesses, have been given a second chance in life, it just goes to show that this really works.

Mrs Bergers children held donor recruitment events across London, throughout the UK and worldwide to raise awareness of the need for more Jewish and ethnic minority bone marrow donors.

The #Spit4Mum campaign via Twitter and Facebook proved so successful the brother and sister helped increase the number of Jewish people on the Anthony Nolan register by 1,191 - more than ten times the previous year's total of 107.

They now hope that more of the people they inspired to join the register will be able to help future patients.

On average, only one in 1,200 people on the register are ever asked to donate - making the five new donors all the more impressive.

And five agonising months, a match was finally found for Sharon she underwent the crucial surgery, and today is making a good recovery.

Link:
#Spit4Mum campaign helps save five people's lives

Recommendation and review posted by Bethany Smith